Industry-Sponsored Research Week
Industry-Sponsored Research Management sample issue

Henry Ford Health System signs research and license agreements advancing exosome technology for repair of brain injury


By David Schwartz
Published: July 17th, 2018

Henry Ford Health System has inked a sponsored research and licensing deal with biopharma company NeuroTrauma Sciences, LLC, to advance Henry Ford’s pioneering exosome technology for the treatment of stroke, traumatic brain injury (TBI), and neuropathies. The research will be carried out under a newly-formed subsidiary of NTS, NeurExo Sciences, LLC (NXS).

The new company is licensing exosome IP and will fund related research projects headed by principal investigator Michael Chopp, PhD, director of the Neurosciences Institute at Henry Ford Hospital. NXS gets worldwide rights to product candidates resulting from the IP and sponsored research coming out of the lab. 

Chopp’s research team has completed proof-of-principle studies in animal models showing how exosomes can amplify the body’s own neurological repair mechanisms and potentially improve long-term neurological outcomes following brain injury.

“Our studies in multiple pre-clinical models indicate that exosomes have the potential to provide significant therapeutic benefits to enhance the recovery from stroke or traumatic brain injury, and potentially with a better safety profile and greater efficacy than their parent or progenitor cells,” said Chopp. “Success of this novel approach may lead to a shift in the treatment paradigm for TBI, stroke and neurological disease.”

“We are delighted to collaborate with Dr. Chopp and his research team to advance the next generation of cell-based therapies,” said Carl Long, NeuroTrauma Sciences and NeurExo Sciences Co-founder and CEO. “We believe that exosome technology has the potential to serve as a transformational platform for multiple neurological conditions — including stroke, concussion and other traumatic brain injuries — and NeuroTrauma Sciences is excited to be a part of it.”

“Henry Ford researchers are pioneers in the exosome field and the NeuroTrauma Sciences team recognized the tremendous potential of our technology and world leading scientists,” said Mark Coticchia, vice president & chief innovation officer of Henry Ford Health System. “We appreciate their support in pursuing the development of this cutting-edge technology with these agreements, and their commitment to investing in the broader Detroit scientific community with the formation of this new company.”

Source: Markets Insider

Posted under: Industry-Sponsored Research Week

Twitter Facebook Linkedin Pinterest Email

No Comments so far ↓

There are no comments yet...Kick things off by filling out the form below.

Leave a Comment